Participant no. 3: Walter Birchmeier, Max Delbrück Center, Berlin, Germany
Institution
The Max Delbrück Center is a large Research complex located in Berlin Buch and comprising three major divisions conducting research in cardiovascular diseases, cancer and function and dysfunctions of the nervous system. It houses in excess of a thousand scientists and clinicians and offers a modern infrastructure, state of the art equipment, and excellent support facilities throughout, including facilities for mouse research.
Walter Birchmeier is the lead participant and, together with his team, he will lead the work in two areas of the SFMET project,namely:
- Cooperation between the MET, WNT and chemokine pathways in tumour invasion
- SHP-2 inhibitors
Profile of the Group
Walter Birchmeier was Scientific Director of the Max Delbrück Center from 2004-2008 and is Professor at the Charité/Humboldt University Berlin. Major contributions to the HGF/SF and MET field include the essential role of GAB-1 in MET signalling and recent genetic evidence that MET is essential for keratinocyte migration in wound repair.
Jane Holland is a senior post-doctoral fellow who will work on the interaction between the MET, WNT and chemokine pathway in tumour invasion and metastasis together with one technician (Regina Vogel).
Katja Grossmann is a postdoctoral fellow, working on SHP-2 conditional mutagenesis in the peripheral nervous system, together with one technician.
Regina Willecke is a graduate student, working on SHP-2 conditional mutagenesis in the kidney.
Özlem Akilli-Öztürk is a graduate student, working on conditional mutagenesis of GAB-1 in the skin.
Chris Eckert is a technician who works on the SFMET project, in particular on SHP-2 inhibitors.